PEDIATRICS Vol. 36 No. 6 December 1965, pp. 869-876
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sunshine, P.
Right arrow Articles by Kriss, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sunshine, P.
Right arrow Articles by Kriss, J. P.

SURVIVAL TIME OF CIRCULATING LONG-ACTING THYROID STIMULATOR IN NEONATAL THYROTOXICOSIS: IMPLICATIONS FOR DIAGNOSIS AND THERAPY OF THE DISORDER

Philip Sunshine M.D.1, Howard Kusumoto M.D.1, and Joseph P. Kriss M.D.1

1 Departments of Pediatrics, Medicine, and Radiology, Stanford University School of Medicine, Stanford, California

We have described an infant with neonatal thyrotoxicosis who developed supraventricular tachycandia, goiter, and periorbital edema. Both the baby's and mother's sera contained the long-acting thyroid stimulator (LATS). While the level of LATS remained unchanged in the serum of the mother, it rapidly fell in the serum of the infant. The biological half-life of LATS in the infant's serum was calculated to be 6 days, and by the age of 21 days no LATS activity could be detected. Based on these findings, antithyroidal treatment which had been instituted soon after birth was discontinued on the thirty-eighth day without recurrence of signs or symptoms of thyrotoxicosis.

In addition to conventional antithyroid therapy for thyrotoxicosis, exchange transfusion and prenatal corticosteroid therapy of the mother may be considered when neonatal or maternal serum LATS titers, respectively, are very high.

Submitted on February 23, 1965
Accepted on March 18, 1965




This article has been cited by other articles:


Home page
 NeoReviewsHome page
M. I. Hernandez and K.-W. Lee
Neonatal Graves Disease Caused by Transplacental Antibodies
NeoReviews, July 1, 2008; 9(7): e305 - e309.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
A L Ogilvy-Stuart
Neonatal thyroid disorders
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2002; 87(3): F165 - 171.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
C. Farrehi
Accelerated Maturity in Fetal Thyrotoxicosis
Clinical Pediatrics, March 1, 1968; 7(3): 134 - 137.
[Abstract] [PDF]